Pharmacovigilance in Yemen - Alshakka, Mohammed
23,99 €
inkl. MwSt.

Versandfertig in 6-10 Tagen
  • Broschiertes Buch

Adverse drug reactions (ADRs) are one of the important causes of morbidity and mortality. In order to minimize the harmful effects of medicines, countries have developed their own pharmacovigilance mechanisms. Yemen is a developing country in South West Asia with a National Pharmacovigilance Program (NPP). The current NPP in Yemen has limited coverage and receives only limited ADR reports. Though the program is successful to a certain extent, still there is a scope for improvement. This booklet discusses the drug regulation in Yemen, describing the existing limitations of these regulations,…mehr

Andere Kunden interessierten sich auch für
Produktbeschreibung
Adverse drug reactions (ADRs) are one of the important causes of morbidity and mortality. In order to minimize the harmful effects of medicines, countries have developed their own pharmacovigilance mechanisms. Yemen is a developing country in South West Asia with a National Pharmacovigilance Program (NPP). The current NPP in Yemen has limited coverage and receives only limited ADR reports. Though the program is successful to a certain extent, still there is a scope for improvement. This booklet discusses the drug regulation in Yemen, describing the existing limitations of these regulations, demonstrating the need for pharmacovigilance and go throughout the different stages of pharmacovigilance activities in Yemen and finally how to foster pharmacovigilance activities to achieve the desired health care in Yemen. We hope that this booklet will serve as a useful reference for those individuals and organizations who are interested in Pharmacovigilance.
Autorenporträt
Dr.Mohamed Alshakka completed his Master degree in pharmacy from Ernst-Moritz-Arndt University Greifswald and his PhD in Pharmacoepidemiology from Universiti Sains Malaysia 2013. Later he joined Aden University in Yemen as Assistant Professor in Faculty of Pharmacy. He appointed as a Director of the Yemeni Pharmacovigilance Center in 2014.